Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

Key Points

• Silence Therapeutics shares rose 5.8% to $14.32, trading above their 50-day and 200-day moving averages, though the company remains unprofitable with a negative P/E ratio.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $53.50; targets range from $32 to $75, but Weiss Ratings maintains a “sell” rating.
• The clinical-stage RNAi biotechnology company missed quarterly EPS estimates, reporting a loss of $0.26 versus an expected loss of $0.14. Its pipeline includes SLN360 for cardiovascular risk reduction and SLN124 for blood and iron-related disorders, while institutional investors own 98.73% of the stock.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) were up 5.8% during mid-day trading on Tuesday . The stock traded as high as $14.50 and last traded at $14.32. Approximately 494,885 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 552,179 shares. The stock had previously closed at $13.53.

Analysts Set New Price Targets

Several research firms have commented on SLN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Silence Therapeutics in a research note on Friday, July 17th. Morgan Stanley boosted their target price on Silence Therapeutics from $25.00 to $32.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Finally, Cantor Fitzgerald began coverage on Silence Therapeutics in a report on Wednesday, June 24th. They set an "overweight" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $53.50.

Silence Therapeutics Stock Performance

The firm's 50-day simple moving average is $11.61 and its 200 day simple moving average is $8.17. The company has a market capitalization of $891.71 million, a PE ratio of -11.57 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. As a group, equities analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -1.03 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLN. XTX Topco Ltd acquired a new position in Silence Therapeutics in the 4th quarter valued at about $71,000. Citadel Advisors LLC purchased a new position in shares of Silence Therapeutics during the 3rd quarter worth $112,000. Massar Capital Management LP acquired a new stake in shares of Silence Therapeutics during the second quarter worth $115,000. GAMMA Investing LLC boosted its holdings in shares of Silence Therapeutics by 18.1% during the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company's stock worth $121,000 after purchasing an additional 1,698 shares during the last quarter. Finally, AXQ Capital LP purchased a new stake in shares of Silence Therapeutics in the second quarter valued at $138,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source